What Is 2-succinylbenzoate synthase

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 15, 2026

Quick Answer: 2-Succinylbenzoate synthase (MenI) is an enzyme involved in the bacterial menaquinone (vitamin K2) biosynthesis pathway, catalyzing the conversion of o-succinylbenzoyl-CoA to 2-succinylbenzoate. It plays a critical role in electron transport in many pathogenic bacteria, making it a potential antimicrobial drug target.

Key Facts

2-Succinylbenzoate synthase is also known as MenI and has EC number 4.2.1.118
It catalyzes a dehydration reaction in the menaquinone biosynthesis pathway
The enzyme is found in bacteria such as Escherichia coli and Bacillus subtilis
MenI is not present in humans, making it a promising target for antibiotics
Structural studies of MenI were first published in 2010 using X-ray crystallography

Overview

2-Succinylbenzoate synthase, also known as MenI, is an essential enzyme in the menaquinone (vitamin K2) biosynthetic pathway in bacteria. This pathway is crucial for the production of electron carriers used in anaerobic respiration, especially in pathogenic species.

MenI catalyzes the conversion of o-succinylbenzoyl-CoA to 2-succinylbenzoate through a dehydration reaction. As humans do not synthesize menaquinone via this route, MenI represents a promising target for developing selective antibacterial agents.

Enzyme Classification: MenI is classified under EC number 4.2.1.118, indicating its role as a lyase that removes water.
Substrate Specificity: The enzyme acts specifically on o-succinylbenzoyl-CoA, converting it into 2-succinylbenzoate and CoA.
Gene Name: In Escherichia coli, the gene encoding this enzyme is called menI, part of the men operon.
Pathway Role: It functions in the fourth step of the classical futalosine-independent menaquinone biosynthesis pathway.
Structural Data: The first crystal structure of MenI was resolved in 2010 at a resolution of 2.1 Å.

How It Works

MenI operates through a precise biochemical mechanism involving substrate binding, dehydration, and product release. Its active site contains conserved residues critical for catalysis, particularly histidine and aspartate, which facilitate proton transfer.

Reaction Type: MenI performs a dehydration reaction, removing a water molecule from o-succinylbenzoyl-CoA to form 2-succinylbenzoate.
Catalytic Residues:His83 and Asp87 in E. coli are essential for proton abstraction and stabilization of intermediates.
Coenzyme A Release: The reaction releases CoA as a byproduct, which can be recycled in other metabolic pathways.
Substrate Binding: The enzyme binds its substrate through hydrogen bonding and hydrophobic interactions in a deep active site pocket.
pH Optimum: MenI exhibits maximum activity at pH 7.5–8.0, typical for cytoplasmic bacterial enzymes.
Temperature Stability: The enzyme remains functional up to 45°C but denatures rapidly above 50°C.

Comparison at a Glance

Below is a comparison of MenI with other enzymes in the menaquinone pathway based on function, gene name, and biochemical properties.

Enzyme	Gene	EC Number	Reaction Catalyzed	Organism
2-Succinylbenzoate synthase	menI	4.2.1.118	Dehydration of o-succinylbenzoyl-CoA	E. coli
1,4-Dihydroxy-2-naphthoate synthase	menB	4.1.3.36	Cyclization to naphthoquinone ring	E. coli
Menadione reductase	menD	2.2.1.9	Thiamine diphosphate-dependent condensation	B. subtilis
Demethylmenaquinone methyltransferase	menH	2.1.1.163	Methylation of demethylmenaquinone	S. aureus
MenA (1,4-dihydroxy-2-naphthoate prenyltransferase)	menA	2.5.1.74	Prenylation of naphthoquinone	E. coli

These enzymes collectively form the core of the menaquinone biosynthesis pathway. Unlike MenI, several of these enzymes have been targeted in drug development, but MenI remains underexploited despite its specificity to bacteria.

Why It Matters

Targeting MenI offers a strategic advantage in developing narrow-spectrum antibiotics that disrupt bacterial energy metabolism without harming human cells. Its absence in mammals makes it an ideal candidate for antimicrobial design.

Antibiotic Development: Inhibitors of MenI could lead to new drugs targeting Mycobacterium tuberculosis, which relies on menaquinone.
Selective Toxicity: Because humans use phylloquinone (K1) instead of menaquinone, drugs targeting MenI avoid off-target effects.
Drug Resistance: Novel targets like MenI are critical in combating multi-drug resistant pathogens such as MRSA.
Metabolic Engineering: Understanding MenI aids in engineering vitamin K2-producing bacterial strains for supplements.
Structural Insights: Crystal structures enable structure-based drug design to inhibit MenI activity.
Biotechnological Applications: MenI is used in synthetic biology platforms to optimize anaerobic fermentation processes.

Continued research into 2-succinylbenzoate synthase enhances our ability to design next-generation therapeutics and deepen understanding of bacterial metabolism. Its role in a conserved and essential pathway underscores its biological and medical significance.